Confusion Over Anti-Clotting Therapy Hinders Drug-Eluting Stent Rebound
This article was originally published in The Gray Sheet
Blanket recommendations for one year of dual antiplatelet therapy for patients who receive drug-eluting stents may be the biggest cloud over the market for the devices, cardiologists suggest
You may also be interested in...
Starts & Stops is a regular feature in Medtech Insight highlighting noteworthy clinical trial announcements, initiations, completions, and suspensions tracked by Meddevicetracker. This edition covers the start of 2018, which includes important trial announcements from Abbott, Boston Scientific, Medtronic, Edwards and many more. The Stops & Starts feature will be switching to a weekly schedule as of March 5 to offer more timely updates on medical device trials.
In patients implanted with drug-eluting stents, dual antiplatelet drug therapy beyond one year significantly reduces the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events compared to aspirin alone, but also increase the risk of bleeding, the Dual Antiplatelet Therapy Trial show.
FDA is contributing $1.5 million to a large, collaborative clinical study designed to find out the optimum length of time to give anti-clotting drugs to patients with coronary drug-eluting stents